Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines.

Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world.

Mayne Pharma also has two full-service contract development and manufacturing organizations (CDMO) servicing clients worldwide:

Metrics Contract Services – Based in Greenville, NC, US

Mayne Contract Services – Based in Salisbury, SA, Australia

Contact Info:
Address: 1538 Main North Road, Salisbury South, SA 5106, Australia
Website: www.maynepharma.com
Phone: 618 8209 2666

Medical Developments International (MDI) is one of Australia’s leading specialised healthcare companies. With an industry leading range of products in the areas of pain management, asthma and resuscitation, plus veterinary equipment, MDI has supplied healthcare professionals and patients innovative solutions since 1971.

MDI is a publicly listed company on the Australian Stock Exchange with both its head office and state of the art manufacturing facilities located in Victoria, Australia.

MDI manufacture the innovative pain relief product, Penthrox® that has been widely adopted by organisations throughout Australia.

MDI has a proud history in human and veterinary medicine, throughout Australia as well as internationally. For over 30 years MDI's key products have helped healthcare professionals achieve better health outcomes for their patients

MDI is compliant with Good Manufacturing Practices as well as ISO 13485 for the manufacture of several of its products (including both pharmaceutical and medical products). Several MDI products are also CE marked, enabling them to be sold into the European Community.

MDI manufactures Analgesics, Asthma and COPD Management, Oxygen Delivery, Carbon Dioxode Absorbers and Veterinary Anesthesia Machines.

Contact Info:
Address: Melbourne, Victoria
Website: www.medicaldev.com
Phone: 613 9547 1888

Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases.

Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak.

Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).

Opthea is committed to improving vision in patients suffering with retinal eye diseases.

Contact Info:
Address: Level 1, 10 Wallace Avenue, Toorak, Melbourne, VIC 3142, AU

Website: www.opthea.com
Phone: 613 9826 0399

Pharmaxis Ltd is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue.

Pharmaxis is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that is scheduled to begin recruitment in Q1 2021. PXS‐5505 is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer.

Other drug candidates being developed from Pharmaxis’ amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and inflammatory diseases such as Duchenne Muscular Dystrophy.

Pharmaxis is listed on the Australian Securities Exchange (PXS).

Contact Info:
Address: 20 Rodborough Road Frenchs Forest NSW 2086, AUSTRALIA
Website: www.pharmaxis.com.au
Phone: 612 9454 7200

Vita Life Sciences is an Australian owned healthcare company that is listed on the Australian Securities Exchange (ASX:VLS). Our brand portfolio includes, Herbs of Gold, VitaHealth, VitaScience and VitaLife.

We produce a wide range of premium supplements, vitamins, minerals, herbs and superfoods catered to all age categories and health conditions.

With approximately 800 registered products, and over 400 employees across Australia and Asia, we work under the philosophy of “thinking internationally, but acting locally”. We have teams of qualified naturopaths, nutritionists, biotechnologists and pharmacists formulating products that are clean, effective and functional.

Vita Life Sciences manufactures health care products, pharmaceuticals, food supplements, vitamins and nutrition.

Contact Info:
Address: Unit 1 / 102 Bath RoadKirrawee, NSW 2232
Website: www.vitalifesciences.com
Phone: 61(2) 9545 2633

IDT Australia Ltd (ASX:IDT) was founded in 1975, IDT Australia is a publicly listed Australian pharmaceutical manufacturing company, based in Boronia Victoria.

Our experienced and awarded team of scientists and specialists provide a flexible and comprehensive service, from early-stage API development, through to finished drug formulation and scaled commercial manufacturing for global distribution.

Our facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. At IDT we value accountability, leadership, curiosity, quality, innovation and driving results.

IDT manufactures FDF, Clinical Packaging, HPAPI, Pharmaceutical Grade, Controlled Substances, Cytotoxicity, Tablets, Capsules, Liquid, Lyophilisation, Stability Test, Phase I, Need Herbal Medicine, Formulation, Analytical Test, Active Pharmaceutical Ingredient, Completed Dosage Form, Aseptic Manufacturing, Clinical Product, GMP, Pharmaceutical and Product Development.

Contact Info:
Address: 45 Wadhurst DriveBoronia, Victoria 3155Australia
Website: en.idtaus.com.au
Phone: 613 9801 8888

Recce Pharmaceuticals Ltd (ASX: RCE, FSE:R9Q) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs.

Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.

Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results to date. Recce Pharmaceuticals has manufacturing facilities in Australia and clinical research partners in the USA.
Recce Pharmaceuticals has validated an automated process to manufacture its lead compound ahead of first-in-human clinical trials.

Product : Pharmaceuticals, sepsis, virus, polymers, biotechnology, synthetic polymers, antibiotics, global health, antibiotic resistance, clinical trials, sepsis, infectious disease , FDA and ASX.

Contact Info:
Address: L36, 1 Macquarie Place, Gateway Tower, Sydney, NSW 2000, AU
Website: www.recce.com.au
Phone: 61(2) 9256 2571